What does CanBas Co., Ltd. do?
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and…
What is CanBas Co., Ltd.'s P/E and P/B ratio?
CanBas Co., Ltd. has a P/E ratio of -11.1 and a P/B ratio of 8.84.
What is CanBas Co., Ltd.'s debt-to-equity ratio?
CanBas Co., Ltd. has a debt-to-equity ratio of 0.00.
How much does CanBas Co., Ltd. owe compared with what it owns?
CanBas Co., Ltd. owes ¥0.08 for every ¥1 it owns (balance sheet Jun 2026), which is low.
What is CanBas Co., Ltd.'s Positivity rank?
CanBas Co., Ltd. is ranked #9,641 of 10,750 companies globally and #3,583 of 3,683 in Japan on PositoAI, with a Positivity Score of 15,385.
Does CanBas Co., Ltd. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for CanBas Co., Ltd..
Where can I read the latest news about CanBas Co., Ltd.?
Recent headlines about CanBas Co., Ltd. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does CanBas Co., Ltd. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of CanBas Co., Ltd.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.